NuPathe Inc  

(Public, NASDAQ:PATH)   Watch this stock  
Find more results for PATH
0.0000
- Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week     -
Open     -
Vol. 0.00
Mkt cap     -
P/E     -
Div/yield     -
EPS -2.24
Shares 31.33M
Beta     -
Inst. own 58%
Mar 24, 2014
Q4 2013 Nupathe Inc Earnings Release (Estimated)
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '13) 2012
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -132.20% -79.84%
Return on average equity -298.54% -865.71%
Employees 14 -
CDP Score - -

Address

SUITE 300, 7 GREAT VALLEY PARKWAY
MALVERN, PA 19355
United States - Map
+1-610-2320800 (Phone)
+1-610-2320571 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

NuPathe, Inc. develops therapeutics for diseases of the central nervous system including neurological and psychiatric disorders. The Companys products are NP201 for the continuous symptomatic treatment of Parkinson's disease and NP202 for the long-term treatment of schizophrenia and bipolar disorder. The Company completed a pivotal Phase III clinical trial for Zelrix, an active, single-use transdermal sumatriptan patch for the treatment of acute migraine.